Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MF MDI · 1 trial · 1 indication
This endpoint reflects changes in lung function data (forced expiratory volume in 1 second) measured across 0 to 60 minutes post-dose (at 0, 5, 15, 30 and 60 minutes) and averaged across study visits in the Treatment Period (Day 1, Week 1, Week 4, Week 8 and Week 12) compared to Baseline. Baseline was the average of % predicted FEV1 values at 30 min and 0 min pre-dose. At each visit, the area under the curve is calculated over the post-dose timepoints. Units are standardized to percent predicted FEV1 by dividing the AUC calculation by the duration of the observed AUC.
An Adverse Event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition temporally associated with the use of the Sponsor's product, is also an AE.
An Adverse Event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition temporally associated with the use of the Sponsor's product, is also an AE.
| Arm | Type | Description |
|---|---|---|
| MF/F MDI 100/10 mcg BID | EXPERIMENTAL | Eligible participants will be assigned randomly to receive double-blinded MF/F MDI 100/10 mcg BID for 24 weeks. |
| MF MDI 100 mcg BID | ACTIVE_COMPARATOR | Eligible participants will be assigned randomly to receive double-blinded MF MDI 100 mcg BID for 24 weeks. |
| Name | Type | Description |
|---|---|---|
| MF MDI 100 mcg BID (Open Label) | DRUG | Eligible participants will receive open-label MF MDI 100 mcg BID during a 2-week run-in period. |
| MF/F MDI 100/10 mcg BID | DRUG | After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF/F MDI 100/10 mcg BID. |
| MF MDI 100 mcg BID | DRUG | After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF MDI 100 mcg BID. |
| Albuterol/Salbutamol PRN | DRUG | Participants may use study-provided short-acting beta agonist (SABA), albuterol/salbutamol, as needed (PRN) for the relief of asthma symptoms. |
| Prednisone/Prednisolone | DRUG | Participants may use a systemic corticosteroid (prednisone/prednisolone) for acute asthma worsening per investigator discretion. |
Inclusion Criteria: * Has a diagnosis of asthma of ≥ 6-months duration according to the Global Initiative for Asthma (GINA) guidelines * Has asthma that is adequately controlled on a stable dose of inhaled corticosteroid (ICS) combined with long-acting beta-agonist (LABA) ≥ 4 weeks * Is able to dem...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
MF MDI is an investigational inhaled combination therapy being developed by Organon & Co. for persistent asthma. It combines mometasone furoate with formoterol fumarate and is delivered as a metered dose inhaler. It is a small molecule product in Phase 3 development.
MF MDI is being studied for the treatment of persistent asthma in children aged 5 to 11 years. The Phase 3 trial evaluated the combination of mometasone furoate and formoterol fumarate against mometasone furoate alone in pediatric patients with persistent asthma.
MF MDI is being developed by Organon & Co., which trades under the ticker OGN. Organon is the sponsor of the Phase 3 program studying the mometasone furoate and formoterol fumarate combination inhaler in pediatric persistent asthma.
MF MDI is in Phase 3 development. The program includes one completed Phase 3 trial, and MF MDI is investigational rather than approved. The completed study was randomized, double-blind, and actively controlled, enrolling 181 participants.
MF MDI has been studied in the Phase 3 trial NCT02741271, titled a study of efficacy and long-term safety of mometasone furoate in combination with formoterol fumarate versus mometasone furoate in children aged 5 to 11 years with persistent asthma. That trial is completed and enrolled 181 participants.